What metabolites are removed by CRRT except creatinine?

Yue Li2, Wenhua Liu2, Kaijiang Yu1*, Hongliang Wang2* and Changsong Wang1*

© The Author(s) 2022. Open Access
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Trial registration Role and mechanism of intestinal flora in acute kidney in sepsis (ChiCTR2100049312). Registered 29 July 2021.

Continuous renal replacement therapy (CRRT) involves the removal of water and solute by simulating the filtration of normal glomeruli through convection and diffusion [1, 2]. Generally, solutes weighing less than 50,000 daltons can be filtered out [3]; this includes common small molecular substances and medium-sized molecular substances [4, 5]. The loss of inorganic substances in CRRT has received sufficient attention. Some trace elements and minerals, such as K⁺, Na⁺, Ca²⁺, HCO₃⁻ and glucose, are supplemented during CRRT. However, there is no relevant experimental research on whether organic matter will be lost, in this process, how much will be lost, and how it will affect the body. Thus, the plasma and the ultrafiltrates of AKI patients before and after 24 h of CRRT were investigated in this study based on gas chromatography-tandem time-of-flight mass spectrometry ((GC–TOF–MS)) metabolomics to explore the metabolites lost in the plasma during CRRT and the metabolites in the ultrafiltrate.

This study is a prospective study that aims to screen the differential metabolic markers in the plasma and ultrafiltrates of in AKI patients before and after CRRT for 24 h based on GC–TOF–MS nontargeted metabolomics. The standard for staging AKI is based on the Kidney Disease Improving Global Outcomes (KDIGO) definition, which defines injury as an increase in serum creatinine (Scr) by 50% or more and a decline in urine output to < 0.5 mL/kg/hr for 6–12 h. All subjects signed written informed consent before enrollment. This experiment was performed to investigate AKI patients who underwent CRRT in the Department of Critical Medicine of the Second Affiliated Hospital of Harbin Medical University from August 2021 to October 2021. All enrolled patients were treated with a CRRT dialyzer (Prismaflex M100), which was replaced every 24 h. The inclusion criteria were as follows: 1. AKI patients over 18 years old (including 18 years old) and under 65 years old (including 65 years old) that were admitted to the ICU for the first time; 2. patients who underwent CRRT for more than 24 h; and 3. patients who signed informed consent.

A total of 16 AKI patients were enrolled from August 2021 to October 2021. The demographic and clinical data of the participants, including blood samples before CRRT (pre-CRRT), blood samples 24 h after CRRT (post-CRRT), and ultrafiltrate 24 h after CRRT, are detailed in Tables 1 and 2. The differential metabolites in the pre-CRRT group, post-CRRT group, and ultrafiltrate group (Fig. 1) were mainly composed of sugars, fatty acids, amino acids, lipids, carnitine derivatives, and other substances. N-formyl-L-methionine 2, one of the basic units of protein, is the only essential amino acid containing sulfur. It is closely related to the metabolism...
of various sulfur-containing compounds in organisms, and its absence can cause anorexia, slow growth, no weight gain, kidney swelling, and liver iron accumulation, finally resulting in liver necrosis or fibrosis. Methionine supplementation can be used to prevent and treat chronic or acute hepatitis, liver cirrhosis, and other liver diseases. Lactose is a reducing sugar that is the source of human heat, similar to other sugars. In addition to supplying energy in humans, it also has physiological functions that are different from other sugars. Lactose is not digested and absorbed in the human stomach. However, it can reach the intestine, promote the production of some lactic acid bacteria in the human intestine, inhibit the growth of spoilage bacteria, and contribute to the peristalsis of the intestine. Concurrently, the production of lactose is conducive to the absorption of calcium and other substances. Lysine is one of the essential amino acids of the human body. It can promote human development, enhance immune function, regulate human metabolic balance, and improve the function of the central nervous system. Cystine releases sulfuric acid and increases the detoxification function of the whole metabolic system when metabolized. Additionally, it will assist the supply of insulin, promote cell redox, make liver function vigorous, enhance leukocyte proliferation, and prevent the development of pathogens. These substances beneficial to the body were detected in the CRRT waste liquid bag. If they can be actively supplemented, they may have a positive effect on the body.

Critically ill patients with AKI, CRRT may contribute to the loss of organic metabolites, such as fatty acids, lipids, carnitine derivatives, and other substances. Loss of these organic metabolites may contribute harm; however, interventional trials evaluated at replacement and supplementation have not been performed. This should be the focus of future clinical trials.

**Table 1** Characteristics of CRRT patients in ICU

| Characteristics       | Pre-CRRT n (16) | Post-CRRT n (16) | P     |
|-----------------------|-----------------|------------------|-------|
| T, °C                 | 37.03 ± 0.79    | 36.50 ± 0.30     | 0.0178|
| HR, bmp               | 114.25 ± 26.25  | 76.63 ± 8.34     | <0.0001|
| MAP, mmHg             | 71.79 ± 29.31   | 97.63 ± 8.34     | 0.001 |
| RR, bmp               | 23.50 ± 8.18    | 14.94 ± 2.29     | <0.0001|
| PH                    | 7.36 ± 0.17     | 7.13 ± 0.04      | <0.0001|
| Lactic acid, mmol/L   | 4.16 ± 3.66     | 1.90 ± 0.76      | <0.0001|
| Serum glucose, mmol/L | 6.72 ± 1.65     | 6.11 ± 1.00      | 0.107 |
| Leukocyte, × 10^9/L   | 14.04 ± 6.01    | 12.98 ± 3.21     | 0.2688|
| Platelet, × 10^9/L    | 142.94 ± 99.91  | 115.31 ± 55.20   | 0.1704|
| TBil, mg/dl           | 516.19 ± 54.57  | 325.44 ± 100.22  | 0.0002|
| Crea, μmol/L          | 23.02 ± 12.28   | 20.32 ± 10.83    | 0.2572|
| APACHE-II             | 25.75 ± 2.41    | 24.25 ± 1.48     | 0.0211|
| SOFA                  | 16.31 ± 2.41    | 13.25 ± 1.53     | 0.0022|

**Table 2** Characteristics of CRRT patients in ICU

| Characteristics       | Number and Frequency |
|-----------------------|----------------------|
| Age, y                | 57 ± 15              |
| Sex, M                | 10(62.5%)            |
| BMI, kg/m²            | 23.88 ± 3.76         |
| BMR, kJ/(m² h)        | 2.5 ± 11.67          |
| Medications           | 16                   |
| Antibiotic Seralbumin | 3                    |
| Nutritional Support(EN/TPN/NPO) | 11/3/2         |
| Insulin therapy       | 12(75%)              |

T temperature, HR heart rate, MAP mean arterial pressure, RR respiration, TBil total bilirubin, APACHE-II acute physiologic assessment and chronic health evaluation II, SOFA sequential organ failure assessment, ICU intensive care unit

P < 0.05 was considered statistically significant

**Figure 1** Metabolites differentially expressed in pre-CRRT group, post-CRRT group and ultrafiltrate group. Heat map summarizing level fold changes of significantly altered metabolites in GC–TOF–MS data. Red and blue represent higher and reduced concentrations of metabolites in the pre-CRRT group, post-CRRT group, and ultrafiltrate group.
Fig. 1  
(a) Metabolites differentially expressed in pre-CRRT group and ultrafiltrate group. 
(b) Metabolites differentially expressed in post-CRRT group and ultrafiltrate group. 
(c) Metabolites differentially expressed in pre-CRRT group and post-CRRT group.
Fig. 1 continued

Acknowledgements
The authors thank all ICU staff for their commitment and significant effort.

Author contributions
Li Y, Yu KJ, Wang HL and Wang CS designed the research; Li Y, Liu WH and Wang CS performed the research; Li Y analyzed the data; Li Y wrote the paper; Li Y and Liu WH collected data. All authors read and approved the final manuscript.

Funding
NSFC—Regional Innovation and Development Joint Fund U20A20366; Key projects of NSFC Technology Department and Provincial Natural Science Foundation Outstanding Youth Project (NO. JQ2021H003).

Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate
The study protocol was approved by the ethics committee of each allied center (approval number KY2021-188), and signed informed consent forms were collected from all study subjects or their families.

Consent for publication
Written informed consent was obtained from the patient for publication. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Received: 21 September 2022   Accepted: 28 October 2022
Published online: 14 November 2022

References
1. Bellomo R, Baldwin I, Fealy N. Prolonged intermittent renal replacement therapy in the intensive care unit. Crit Care Resusc. 2002;4(4):281–90 (PMID: 16573441).
2. Huang Z, Letteri JJ, Clark WR, Ronco C, Gao D. Operational characteristics of continuous renal replacement modalities used for critically ill patients with acute kidney injury. Int J Artif Organs. 2008;31(6):525–34. https://doi.org/10.1177/039139880803100608.
3. Sold M. Extrarenale Eliminationsverfahren bei akutem Nierenversagen [Extrarenal elimination procedures in acute kidney failure]. Anaesthesist. 1990;39(11):569–86 (PMID: 2288406).
4. Naorungroj T, Serpa Neto A, Murugan R, Kellum JA, Bellomo R. Continuous renal replacement therapy: the interaction between fluid balance and net ultrafiltration. Am J Respir Crit Care Med. 2021;203(9):1199–201. https://doi.org/10.1164/rccm.202011-4097LE.
5. Murdeshwar HN, Anjum F. Hemodialysis. 2021 Dec 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2022. (PMID: 33085443).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.